Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials

Thomas Biebera Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany;b Christine Kühne - Center for Allergy Research and Education, Davos, SwitzerlandCorrespondence[email protected]
View further author information

Norito Katohc Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information

Eric L. Simpsond Department of Dermatology, Oregon Health & Science University, Portland, OR, USAView further author information

Marjolein de Bruin-Wellere Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The NetherlandsView further author information

Diamant Thaçif Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

Antonio Torrelog Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, SpainView further author information

Susanne Grondh Eli Lilly and Company, Indianapolis, IN, USAView further author information

Maher Issah Eli Lilly and Company, Indianapolis, IN, USAView further author information

Xiaoyu Lui TechData Service Company, King of Prussia, PA, USAView further author information

Tracy Cardilloh Eli Lilly and Company, Indianapolis, IN, USAView further author information

Jacob P. Thyssenj Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, DenmarkView further author information

Your download is now in progress and you may close this window